mRNA Vaccines Offer New Possibilities for Tuberculosis Prevention
Preventing tuberculosis and the limits of current vaccines
A review examining the potential of mRNA vaccines for tuberculosis highlights the flexibility of antigen design while identifying the induction of local lung immunity as a key development challenge. It considers new prevention strategies amid a persistent global burden of tuberculosis and variable BCG vaccine effectiveness across vaccination settings and conditions. The paper does not report clinical-trial results demonstrating the preventive efficacy of a new vaccine.
Mycobacterium tuberculosis (Mtb) survives inside cells and can become sequestered within necrotic granulomas. The authors describe this spatial sequestration, along with the time it takes for systemic immunity to reach the lung parenchyma, as barriers to vaccine development.
Designing tuberculosis immunity with mRNA
Messenger RNA (mRNA) vaccine platforms enable antigen production in the body and can induce CD8⁺ T-cell activation. The ability to design multistage fusion antigens targeting both active- and latent-phase Mtb is also presented as an advantage. The review highlights the flexibility of antigen design and the potential to scale up production. However, the abstract provides no specific antigen names, comparator groups, or quantitative preventive effects, so it does not establish superior protection over existing vaccines.
mRNA technology alone cannot resolve Mtb’s sequestration within granulomas or the delay before systemic immunity reaches the lungs. The limitations identified by the authors concern the bacterium’s spatial sequestration and the difficulty of immune access. Mucosal delivery systems that induce lung tissue-resident memory T cells are proposed as a development direction to address these challenges. Sterilizing protection is presented as a goal, not an achieved outcome.
Local lung immunity and practical challenges
Candidate vaccines should be assessed not only for the magnitude of the immune response but also for whether that response is linked to actual protection. The review recommends prioritizing correlates of protection that reflect immunity at the infection site, rather than relying solely on interferon-gamma (IFN-γ) measurements. Safety in people with latent infection and heat-stable formulations for supply to tuberculosis-endemic regions are also identified as development challenges. The abstract does not provide validated correlates of protection, safety results, or specific storage temperatures.
The authors also discuss heterologous prime-boost strategies that administer different vaccines in sequence, as well as combining mRNA vaccines with host-directed therapies. These are research directions proposed by the authors and do not mean that clinical benefit has been demonstrated. A question for future research is whether the advantages of antigen production can be translated into protective immunity that works in the lungs.
Source: Article abstract indexed in Europe PMC.
The persistent global burden of tuberculosis (TB) and the context-dependent efficacy of the Bacillus Calmette-Guérin (BCG) vaccine necessitate the development of innovative prophylactic strategies. mRNA vaccine platforms have emerged as a transformative toolkit, offering unprecedented versatility in antigen design and manufacturing scalability. This inclusive innovation review synthesizes the molecular engineering and immunological mechanisms of mRNA TB vaccines, evaluating their capacity to address the unique challenges posed by the intracellular lifestyle of Mycobacterium tuberculosis (Mtb). mRNA platforms realistically offer superior endogenous antigen production for CD8⁺ T-cell activation and the flexibility to encode multi-stage fusion antigens targeting both active and latent bacilli. However, significant constraints remain; mRNA technology alone cannot resolve the spatial sequestration of Mtb within necrotic granulomas or the "recruitment lag" of systemic immunity to the lung parenchyma. Achieving sterile protection requires a transition toward mucosal delivery systems capable of inducing lung T
This review outlines directions for evaluating and developing mRNA vaccine candidates for tuberculosis. For example, development teams assessing a candidate with a strong IFN-γ response could also examine the relationship between local lung immunity and actual protection. If people with latent infection are included among the intended recipients, safety should be assessed separately; plans to supply endemic regions should also consider the formulation’s temperature stability. These considerations can help evaluate candidates in light of immune-response measures, intended recipients, and supply conditions. However, these are development directions proposed by the review, and the abstract alone cannot establish reductions in infection, disease, or deaths, or indicate when clinical use might begin.